Objectives The clinical landscape in lung cancer treatment has rapidly evolved in recent
years, especially in NSCLC. Real World Data (RWD) can provide insights into …

Background The clinical landscape in non-small-cell lung cancer (NSCLC) treatment has
rapidly evolved in recent years. Real-world data (RWD) can provide insights into current …

Objectives Pembrolizumab was the first programmed cell death receptor ligand 1 (PD-L1)
inhibitor approved 10/2016 for first line monotherapy in mNSCLC patients with high PD-L1 …

Aim: To conduct a retrospective analysis of electronic medical record data to understand real-
world treatment patterns and overall survival (OS) in patients with metastatic non-small-cell …

Background Patients with advanced lung cancer represent a heterogenous population with
varying patterns of metastasis. Those with liver metastases may represent a unique cohort …

Methods We queried the Northwestern Medicine Enterprise Data Warehouse for patients
with newly diagnosed lung cancer in 2019 and 2020 at Northwestern Memorial Hospital …

Background Multiple anti-PD-1/PD-L1 first-line treatment options are approved for advanced
non-small cell lung cancer (NSCLC), including pembrolizumab+ chemotherapy studied in …

Background Advances in mNSCLC diagnosis and treatment have led to a rapidly evolving
patient management landscape. This study aims to describe real-world diagnostic and first …

Background Recently, multiple immunotherapy-based treatment choices have emerged for
the management of advanced non-small cell lung cancer (NSCLC). Pembrolizumab …

Methods Patients were randomized (2: 1) to intravenous pembrolizumab 200 mg or placebo
Q3W for up to 35 cycles (2 years). All patients received pemetrexed and investigator's choice …